ATHE Key Statistics, Chart & Performance
The current stock price of ATHE is 3.33 USD. In the past month the price decreased by -0.89%. In the past year, price decreased by -0.3%.
ATHE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About ATHE
Company Profile
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Company Info
ALTERITY THERAPEUTICS-ADR
Level 14, 350 Collins Street
Melbourne VICTORIA VIC 3000 AU
CEO: David A. Stamler
Employees: 9
Phone: 61393494906
ALTERITY THERAPEUTICS-ADR / ATHE FAQ
What does ATHE do?
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
What is the stock price of ALTERITY THERAPEUTICS-ADR today?
The current stock price of ATHE is 3.33 USD. The price increased by 3.74% in the last trading session.
Does ATHE stock pay dividends?
ATHE does not pay a dividend.
What is the ChartMill rating of ALTERITY THERAPEUTICS-ADR stock?
ATHE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Would investing in ALTERITY THERAPEUTICS-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATHE.
What is the market capitalization of ATHE stock?
ALTERITY THERAPEUTICS-ADR (ATHE) has a market capitalization of 60.36M USD. This makes ATHE a Micro Cap stock.
ATHE Technical Analysis
ATHE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ATHE. While ATHE seems to be doing ok healthwise, there are quite some concerns on its profitability.
ATHE Financial Highlights
Over the last trailing twelve months ATHE reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS increased by 59.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.39% | ||
| ROE | -28.65% | ||
| Debt/Equity | 0 |
ATHE Forecast & Estimates
For the next year, analysts expect an EPS growth of 100% and a revenue growth 1263.83% for ATHE